Document Detail


Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
MedLine Citation:
PMID:  16999658     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To recommend strategies to bridge therapy with low-molecular-weight heparin (LMWH) in obese patients and in patients with renal dysfunction. METHODS: A MEDLINE search was performed of the literature from January 1966-November 2005. Published material dealing with bridging of anticoagulation therapy or short-term use of LMWH therapy in patients with renal dysfunction or obesity was reviewed. The manufacturers of enoxaparin, dalteparin, and tinzaparin were contacted for the references used to determine dosing recommendations. RESULTS: Although LMWH has been commonly used to bridge therapy, our search revealed no trials that specifically examined LMWH bridge therapy in obese patients or in patients with renal dysfunction. However, nine trials using LMWH in obese patients and 14 trials using LMWH in patients with renal dysfunction were identified. When compared with normal-weight individuals, obese patients receiving enoxaparin and dalteparin based on total body weight did not demonstrate higher hemorrhage rates or antifactor Xa levels. Subtherapeutic antifactor Xa levels were more common with once-daily dosing of enoxaparin than with dosing every 12 hours. Enoxaparin accumulates in patients with a creatinine clearance of 30 ml/minute or less; in this population, enoxaparin dosage adjustments have been attempted. Tinzaparin does not accumulate in patients with a creatinine clearance of 20 ml/minute or greater after at least 10 days of dosing. CONCLUSION: Obese patients, weighing 90-150 kg, receiving LMWH for bridge therapy should receive dosages based on total body weight. Unfractionated heparin is recommended in patients weighing more than 150 kg; however, if LMWH is used, antifactor Xa levels should be monitored. Bridging with enoxaparin should be limited to patients with a creatinine clearance greater than 30 ml/minute. The use of enoxaparin 1 mg/kg once/day for patients with a creatinine clearance of 30 ml/minute or less is not recommended for anticoagulation bridge therapy. Tinzaparin may be considered for cross-coverage of high-risk patients with recent or recurrent venous thromboembolism who have a creatinine clearance of at least 20 ml/minute.
Authors:
Kirsten L George-Phillips; Tammy J Bungard
Related Documents :
677818 - Effects of acetazolamide on myotonia.
21331508 - The relationship between high-sensitivity c-reactive protein levels and the severity of...
21507218 - Indications of th1 and th17 responses in cerebrospinal fluid from patients with lyme ne...
9815738 - Pharmacokinetics of carboplatin with and without amifostine in patients with solid tumors.
18384418 - Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide.
23946278 - Clinical phenotypes of chinese primary hyperparathyroidism patients are associated with...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Pharmacotherapy     Volume:  26     ISSN:  0277-0008     ISO Abbreviation:  Pharmacotherapy     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-09-26     Completed Date:  2007-02-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8111305     Medline TA:  Pharmacotherapy     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1479-90     Citation Subset:  IM    
Affiliation:
Regional Pharmacy Services, Capital Health, Anticoagulation Management Service, University of Alberta Hospital, Edmonton, Alberta, Canada. kigeorge@cha.ab.ca
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anticoagulants / therapeutic use*
Heparin, Low-Molecular-Weight / therapeutic use*
Humans
Kidney / drug effects
Kidney Diseases / complications*
Obesity / blood,  complications*
Risk Assessment
Risk Factors
Thromboembolism / prevention & control
Chemical
Reg. No./Substance:
0/Anticoagulants; 0/Heparin, Low-Molecular-Weight

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Nesiritide: harmful or harmless?
Next Document:  Carvedilol versus cardioselective beta-blockers for the treatment of hypertension in patients with t...